Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report.
Lung cancer is the leading cause of cancer death worldwide and the use of novel agents, such as sorafenib has now demonstrated activity in Non Small Cell Lung Cancer. We present a case of a 77-year-old Caucasian male with advanced adenocarcinoma of the lung, who was being treated on clinical trial with single agent sorafenib. After seven weeks of treatment the patient presented to clinic with difficulty walking. Physical exam revealed acral erythema with bollous formation on bilateral soles of his feet. Otoscopic exam revealed bilateral external canal bullous lesion. The patient was diagnosed with plantar erythrodysesthesia with bullous otitis externa, a new toxicities in patients being treated with sorafenib.
Carter
Corey A
CA
CCR, National Cancer Institute, 10 Center Drive, Building 10, Room 12N226, Bethesda, MD 20892, USA. carterca3@mail.nih.gov
Rajan
Arun
A
Giaccone
Giuseppe
G